Clinical trials: FLU
Influenza Disease; Flu
Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults
The purpose of this study is to evaluate the safety and immunogenicity of cell culture-derived, inactivated, subunit influenza vaccine in comparison to licensed Fluvirin vaccine administered to healthy adults ages 18 < 50 years.
- Trial name
- NCT00264576
- Testing
- Influenza Virus Vaccine
- Where
- 4 sites in United States
- Volunteers
- 613 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above
Evaluate the immune response and reactogenicity of H5N1 vaccination in adults aged 18 years and above (as part of a tetravalent vaccine)
- Trial name
- NCT00620815
- Testing
- Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine, Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine
- Where
- 2 sites in Germany
- Volunteers
- 601 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Respiratory Viral Infection
Test-and-treat for Influenza in Homeless Shelters
This study is a stepped-wedge cluster-randomized trial of on-site rapid testing and treatment for influenza in homeless shelters within the Seattle area to determine whether this strategy reduced the incidence of influenza in the…
- Trial name
- NCT04141917
- Testing
- Point-of-care molecular testing and treatment of influenza
- Where
- 9 sites in United States
- Volunteers
- 1,618 people
- Sponsor
- University of Washington
Influenza
A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection
This is a randomized, double-blind, placebo-controlled study that will investigate the safety and clinical activity of a single intravenous (IV) dose of MHAA4549A in adult participants hospitalized with severe influenza A in…
- Trial name
- NCT02293863
- Testing
- MHAA4549A, Oseltamivir
- Where
- 171 sites in Belgium, Brazil and 23 more
- Volunteers
- 168 people
- Sponsor
- Genentech, Inc.
Influenza
A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults
The aim of this study is to determine the efficacy of Fluzone High-Dose compared to standard dose Fluzone for laboratory-confirmed or culture-confirmed influenza caused by influenza types/subtypes that are similar (for…
- Trial name
- NCT01427309
- Testing
- High Dose Trivalent Inactivated Influenza Vaccine, Trivalent Inactivated Influenza Vaccine
- Where
- 113 sites in United States, Canada and 1 more
- Volunteers
- 31,989 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and Above
Demonstrate non-inferiority of the post-vaccination (Day 22) Hemagglutination inhibition (HI) Geometric Mean Titers (GMTs) of trivalent, inactivated, subunit influenza vaccine (TIV) over the corresponding GMTs of the comparator…
- Trial name
- NCT01867021
- Testing
- Fluvirin(TIVf), Agriflu (TIV)
- Where
- 25 sites in Czechia, Philippines and 2 more
- Volunteers
- 2,902 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza
Comparison of Three Licensed Influenza Vaccines
This study will evaluate in detail the way that the immune system responds to three different kinds of flu shots that are licensed in the United States.
- Trial name
- NCT03068949
- Testing
- FluBlok, Fluzone, FluCelVax
- Where
- United States
- Volunteers
- 413 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Respiratory Syncytial Virus
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
The main purposes of Part A of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with a seasonal influenza vaccine (Afluria® Quadrivalent); to evaluate the impact of…
- Trial name
- RSVictory (NCT05330975)
- Testing
- mRNA-1345, Afluria® Quadrivalent, mRNA-1273.214
- Where
- 62 sites in United States
- Volunteers
- 3,317 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults
This trial will assess the immunogenicity and safety of GSK Biologicals' vaccine GSK1557484A, prepared from old concentrated monobulk material, in adults aged 18 to 64 years, when administered up to 5 years following production.
- Trial name
- NCT01416571
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Seasonal Influenza
Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012
This study will evaluate the safety and immunogenicity of a sub-unit, adjuvanted Influenza Vaccine Administered to Elderly Subjects.
- Trial name
- NCT01344057
- Testing
- Seasonal Influenza Vaccine
- Where
- 6 sites in Italy
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age
The present study is designed to evaluate the immunogenicity and safety of a single or double dose of the pandemic influenza candidate vaccine (GSK1562902A), administered following a two-administration schedule (21 days apart) in…
- Trial name
- NCT00397215
- Testing
- Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not), Fluarix
- Where
- 12 sites in Belgium, Italy
- Volunteers
- 437 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide
Primary Objective: Assess the antibody response to influenza vaccine in patients with relapsing form of multiple sclerosis (RMS) treated with teriflunomide compared to a reference population.
- Trial name
- TERIVA (NCT01403376)
- Testing
- teriflunomide, Interferon-β-1, Influenza vaccine
- Where
- 14 sites in Austria, Canada and 3 more
- Volunteers
- 128 people
- Sponsor
- Sanofi
Influenza
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children
The purpose of this trial is to demonstrate the acceptable safety profile and the immunological non-inferiority of the FLU D-QIV vaccine manufactured with this investigational process (FLU D-QIV Investigational Process [IP])…
- Trial name
- NCT02207413
- Testing
- Influsplit Tetra™ vaccine produced by investigational process (IP), Influsplit Tetra™ vaccine produced by licensed process (LP)
- Where
- 53 sites in United States, Bangladesh and 5 more
- Volunteers
- 1,886 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pregnancy
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
This is a pilot, prospective, randomized, open-label clinical trial. During the study, pregnant women will be randomized (1:1) to receive co-administration of a single intramuscular (IM) 0.5 mL dose of US-licensed inactivated…
- Trial name
- Tdap/IIV (NCT02783170)
- Testing
- Tetanus, Diphtheria, and Pertussis Vaccine, 2016-2017 Quadrivalent Inactivated Influenza Vaccine, 2017-2018 Quadrivalent Inactivated Influenza Vaccine
- Where
- 3 sites in United States
- Volunteers
- 81 people
- Sponsor
- Duke University
Seasonal Influenza, Influenza
Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects
This study aims to evaluate the immunogenicity, by means of cell mediated immunity (CMI) and hemagglutination inhibition (HI) assay, and also the safety of a MF59C.1-adjuvanted subunit influenza vaccine compared with a…
- Conditions
- Seasonal Influenza, Influenza, Influenza Due to Unspecified Influenza Virus, Human Influenza
- Trial name
- NCT01342796
- Testing
- MF59C.1-adjuvanted subunit influenza vaccine, Sub unit, Inactivated, Influenza vaccine
- Where
- 2 sites in Belgium
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.
The administration of adjuvanted Trivalent Influenza Vaccine (aTIV) has come to result in a more immunogenic and effective response compared with conventional influenza vaccines in elderly and adults.
- Trial name
- NCT02255279
- Testing
- Adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29), Non-adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29).
- Where
- 3 sites in Mexico
- Volunteers
- 287 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Trial to Collect Safety Data and Sera for Immunogenicity Testing
To provide Centers for Biologics Evaluation and Research (CBER) with sera collected from healthy children receiving the 2006-2007 formulation of the inactivated, split-virion influenza vaccine Fluzone® for further study by the…
- Trial name
- NCT00389857
- Testing
- Influenza Virus Vaccine (Fluzone®)
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)
The purpose of this study is to determine if a Vero cell-derived trivalent seasonal influenza vaccine produced by the modified manufacturing process: 1.
- Trial name
- NCT01773928
- Testing
- Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified), VCIV manufactured with the current manufacturing process (VCIV current), Fluzone®, licensed trivalent influenza vaccine (TIV)
- Where
- 20 sites in United States
- Volunteers
- 1,928 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.
The aim of this study is to evaluate the safety and immunogenicity of Fluzone vaccine (18 years to <65 years of age and ≥ 65 years of age), Fluzone Intradermal vaccine (18 years to <65 years of age), and Fluzone High-Dose vaccine…
- Trial name
- NCT01691339
- Testing
- Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation, Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation, Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation
- Where
- 4 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy
A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine
This prospective annual release study was designed to assess the safety of a monovalent influenza virus vaccine using a new strain recommended for the 2009-2010 influenza season not previously contained in the trivalent…
- Trial name
- MI-MA205 (NCT00873912)
- Testing
- Monovalent influenza virus vaccine
- Where
- 3 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC